18458108. EPSTEIN BARR VIRUS VACCINES simplified abstract (Fred Hutchinson Cancer Center)
Contents
- 1 EPSTEIN BARR VIRUS VACCINES
EPSTEIN BARR VIRUS VACCINES
Organization Name
Inventor(s)
James M. Olson of Seattle WA (US)
Andrew Mcguire of Seattle WA (US)
Barry L. Stoddard of Seattle WA (US)
EPSTEIN BARR VIRUS VACCINES - A simplified explanation of the abstract
This abstract first appeared for US patent application 18458108 titled 'EPSTEIN BARR VIRUS VACCINES
Simplified Explanation
The abstract describes an anti-Epstein Barr Virus (EBV) vaccine that can be used to treat and reduce the risk of EBV infection and associated complications.
- The EBV vaccine antigens are linked to a multimerization domain, such as a circular tandem repeat protein (cTRP) scaffold or a C4b multimerization domain.
- The vaccines aim to treat and reduce the risk of complications related to EBV infection, including infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
Potential Applications
The technology could be applied in the development of vaccines for preventing EBV infection and its associated complications.
Problems Solved
This technology addresses the need for effective prevention and treatment options for EBV infection, which can lead to serious health issues.
Benefits
The use of this vaccine could potentially reduce the incidence of EBV-related diseases and improve overall public health outcomes.
Potential Commercial Applications
This technology has the potential for commercialization in the pharmaceutical industry for the production and distribution of EBV vaccines.
Possible Prior Art
Prior research may exist on the development of vaccines targeting EBV antigens, but the specific approach of linking antigens to multimerization domains as described in this patent application may be novel.
Unanswered Questions
How does this vaccine compare to existing EBV vaccines in terms of efficacy and safety?
The article does not provide information on the comparative effectiveness and safety profile of this vaccine compared to other existing EBV vaccines.
What are the potential challenges in scaling up production and distribution of this vaccine?
The article does not address the potential obstacles or challenges that may arise in scaling up the production and distribution of this EBV vaccine.
Original Abstract Submitted
Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
